SGLT2 inhibitors may improve diastolic function in heart failure with preserved ejection fraction by reducing myofilament stiffness via improved PKG signaling and attenuating oxidative stress.
This review highlights the potential beneficial mechanisms of SGLT2 inhibitors in the pathophysiology of HFpEF, with a focus on contractile and diastolic function.
Heart failure with preserved ejection fraction (HFpEF) is an unsolved and growing concern in cardiovascular medicine. While no treatment options that improve prognosis in HFpEF patients has been established so far, SGLT2 inhibitors (SGLT2i) are currently being investigated for the treatment of HFpEF patients. SGLT2i have already been shown to mitigate comorbidities associated with HFpEF such as type 2 diabetes and chronic renal disease, however, more recently there has been evidence that they may also directly improve diastolic function. In this article, we discuss some potential beneficial mechanisms of SGLT2i in the pathophysiology of HFpEF with focus on contractile function.
Pabel et al. (Fri,) conducted a review in Heart failure with preserved ejection fraction (HFpEF). SGLT2 inhibitors was evaluated. SGLT2 inhibitors may improve diastolic function in heart failure with preserved ejection fraction by reducing myofilament stiffness via improved PKG signaling and attenuating oxidative stress.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: